Clinical trials: Lung Cancer, completed
Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer death worldwide and in the United States. The majority of lung cancers are non-small cell lung cancer (NSCLC). The majority of NSCLC cases are advanced at the time of diagnosis.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, Metastatic NSCLC
- Trial name
- NCT01438307
- Testing
- Cabazitaxel-XRP6258 (3-week cycle), Cabazitaxel-XRP6258 (5-week cycle)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Alabama at Birmingham
Neoplasms, Neoplasm Metastasis
A Study of AK-01 (LY3295668) in Solid Tumors
This two-part study consists of a phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either small cell lung cancer, breast cancer and/or…
- Conditions
- Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT03092934
- Testing
- LY3295668
- Where
- 3 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
Lung Neoplasms, Lung Cancer
CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility
This is a prospective observation study in patients with non-small cell lung cancer (NSCLC) starting either cytotoxic chemotherapy or radiation therapy.
- Conditions
- Lung Neoplasms, Lung Cancer, Neoplasm of Lung, Non Small Cell Lung Cancer
- Trial name
- CITaDeL (NCT03986463)
- Testing
- Circulating tumour DNA (ctDNA)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Skin Melanoma, Squamous Non-small-cell Lung Cancer
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
The goal of this double-blind, randomized study is to establish the equivalence of pharmacokinetic properties, as well as the comparability of safety, immunogenicity and pharmacodynamics of the drug RPH-075 (international…
- Conditions
- Skin Melanoma, Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06307093
- Testing
- RPH-075, Keytruda®
- Where
- 23 sites in Russia
- Volunteers
- 90 people
- Sponsor
- R-Pharm
Mesothelioma, Malignant
Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma
MiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma.
- Trial name
- MiST (NCT03654833)
- Testing
- Rucaparib, Abemaciclib, pembrolizumab & bemcentinib
- Where
- United Kingdom
- Volunteers
- 186 people
- Sponsor
- University of Leicester
Lung Cancer
Intervention to Improve Continuity of Care in Lung Cancer Patients
Many authors have recognized the need to overcome the different barriers to continuity of cancer care, such as inadequate communication between specialists and family physicians (FP), insufficient information provided for the…
- Trial name
- NCT01389739
- Testing
- Multi-faceted intervention to improve continuity of care
- Where
- Canada
- Volunteers
- 206 people
- Sponsor
- Laval University
Advanced Lung Carcinoma, Malignant Female Reproductive System Neoplasm
Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer
This trial will pilot a psychosocial intervention called Conquer Fear Support (CFS) in patients with stage III-IV lung or gynecologic cancer who are experiencing fear of cancer progression.
- Conditions
- Advanced Lung Carcinoma, Malignant Female Reproductive System Neoplasm, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03776253
- Testing
- Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components), Questionnaire Administration
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- City of Hope Medical Center
Malignant Pleural Mesothelioma, Non-small Cell Lung Cancer
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited.
- Trial name
- NCT04480372
- Testing
- Gemcitabine, Atezolizumab
- Where
- 12 sites in Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Lung Cancer
Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006469
- Testing
- carboplatin, paclitaxel, conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medstar Health Research Institute
Lung Cancer
Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC
STUDY DESIGN: This is a retrospective, multi-reader, multi-case, (MRMC) randomized reader study. OBJECTIVE: Primary: The primary objective of this clinical study is to prove that a user aided with ClearRead CT InSight (CRCTI) is…
- Trial name
- NCT02440139
- Testing
- ClearRead CT Insight
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Virginia Polytechnic Institute and State University
Adenocarcinoma of the Lung, Large Cell Lung Cancer
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
This phase II trial is studying how well erlotinib works in treating patients with advanced primary non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00087412
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Can Austrian Lung Specialists' Assessments of Lung Cancer Screening be Influenced by a Fact Box?"
Lung cancer is the most frequently dianosed cancer worldwide. To date, no screening method has been able to establish itself as routinely recommended by the guidelines.
- Trial name
- NCT04819477
- Testing
- Fact box, Cates plot
- Where
- Austria
- Volunteers
- 973 people, healthy volunteers welcome
- Sponsor
- Karl Landsteiner Institute for Lung Research and Pneumological Oncology
COVID-19, Cancer
COVID EHR COHORT at the University of Wisconsin
This cohort study will obtain electronic health record (EHR) data (limited data set) from 21 health systems affiliated with the Cancer Center Cessation Initiative (C3I) network or health systems with large numbers of COVID-19…
- Conditions
- COVID-19, Cancer, Nicotine Dependence, Pulmonary Disease
- Trial name
- CEC-UW (NCT04506528)
- Where
- United States
- Volunteers
- 1,634,381 people
- Sponsor
- University of Wisconsin, Madison
Non-Small Cell Lung Cancer
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of alectinib in participants with ALK-rearranged non-small cell lung cancer who failed crizotinib treatment.
- Trial name
- NCT01871805
- Testing
- Alectinib
- Where
- 42 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
- Trial name
- NCT00059722
- Testing
- ZD6474, ZD1839
- Where
- 48 sites in United States, Argentina and 4 more
- Volunteers
- 160 people
- Sponsor
- Genzyme, a Sanofi Company
Covid-19, Lung Cancer
LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)
This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection.
- Trial name
- GRAVID (NCT04344002)
- Where
- 75 sites in Spain
- Volunteers
- 886 people
- Sponsor
- Spanish Lung Cancer Group
Procalcitonin, Pneumonia
Procalcitonin Test for Differentiation of the Cause of Pneumonia
The purpose of this study is to evaluate the usefulness of procalcitonin test for differentiation of the cause of pneumonia in patients with cancer.
- Conditions
- Procalcitonin, Pneumonia, Cancer
- Trial name
- NCT03350802
- Testing
- procalcitonin test
- Where
- South Korea
- Volunteers
- 649 people
- Sponsor
- National Cancer Center, Korea
Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have relapsed or refractory solid tumors of childhood.
- Conditions
- Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma, Gastrointestinal Stromal Tumor, Lung Metastases
- Trial name
- NCT00030667
- Testing
- imatinib mesylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent…
- Trial name
- NCT00806819
- Testing
- Nintedanib (BIBF1120), Pemetrexed, B12
- Where
- 163 sites in United States, Argentina and 30 more
- Volunteers
- 718 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer, Lung Metastases
AI Prediction Model and Risk Stratification for Lung Metastasis in Colorectal Cancer
Background: To assist clinicians with diagnosis and optimal treatment decision-making, we attempted to develop and validate an artificial intelligence prediction model for lung metastasis (LM) in colorectal cancer (CRC) patients.
- Trial name
- NCT05816902
- Testing
- The location of the patient's treatment
- Volunteers
- 2,779 people
- Sponsor
- Peking Union Medical College
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.